Section 218: Advanced Nutritional Genomics and Personalized Diet in CBS/PSP

Migration, Crosslink

📖

Section 218: Advanced Nutritional Genomics and Personalized Diet in CBS/PSP

active

wiki page Created: 2026-04-02T07:18:59 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-section-218-advanced-n

📖 Wiki Page

therapeutic1573 wordssynced 2026-04-02

Section 218: Advanced Nutritional Genomics and Personalized Diet in CBS/PSP

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Section 218: Advanced Nutritional Genomics and Personalized Diet in CBS/PSP</th>
</tr>
<tr>
<td class="label">MTHFR Genotype</td>
<td>Enzyme Activity</td>
</tr>
<tr>
<td class="label">C677T (wild-type)</td>
<td>100% (normal)</td>
</tr>
<tr>
<td class="label">C677T heterozygous</td>
<td>60% (reduced)</td>
</tr>
<tr>
<td class="label">C677T homozygous (TT)</td>
<td>30% (severely reduced)</td>
</tr>
<tr>
<td class="label">A1298C variants</td>
<td>60-80% activity</td>
</tr>
<tr>
<td class="label">VDR Polymorphism</td>
<td>Location</td>
</tr>
<tr>
<td class="label">TaqI (rs731236)</td>
<td>Exon 9</td>
</tr>
<tr>
<td class="label">FokI (rs2228570)</td>
<td>Exon 2</td>
</tr>
<tr>
<td class="label">BsmI (rs1544410)</td>
<td>Intron 8</td>
</tr>
<tr>
<td class="label">ApaI (rs7975232)</td>
<td>Intron 8</td>
</tr>
<tr>
<td class="label">VDR Genotype</td>
<td>Recommended Vitamin D3</td>
</tr>
<tr>
<td class="label">FokI FF</td>
<td>2000-4000 IU/day</td>
</tr>
<tr>
<td class="label">FokI ff</td>
<td>4000-6000 IU/day</td>
</tr>
<tr>
<td class="label">TaqI tt</td>
<td>Consider higher doses</td>
</tr>
<tr>
<td class="label">Combined risk</td>
<td>4000-8000 IU/day</td>
</tr>
<tr>
<td class="label">APOE Genotype</td>
<td>

...

Section 218: Advanced Nutritional Genomics and Personalized Diet in CBS/PSP

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Section 218: Advanced Nutritional Genomics and Personalized Diet in CBS/PSP</th>
</tr>
<tr>
<td class="label">MTHFR Genotype</td>
<td>Enzyme Activity</td>
</tr>
<tr>
<td class="label">C677T (wild-type)</td>
<td>100% (normal)</td>
</tr>
<tr>
<td class="label">C677T heterozygous</td>
<td>60% (reduced)</td>
</tr>
<tr>
<td class="label">C677T homozygous (TT)</td>
<td>30% (severely reduced)</td>
</tr>
<tr>
<td class="label">A1298C variants</td>
<td>60-80% activity</td>
</tr>
<tr>
<td class="label">VDR Polymorphism</td>
<td>Location</td>
</tr>
<tr>
<td class="label">TaqI (rs731236)</td>
<td>Exon 9</td>
</tr>
<tr>
<td class="label">FokI (rs2228570)</td>
<td>Exon 2</td>
</tr>
<tr>
<td class="label">BsmI (rs1544410)</td>
<td>Intron 8</td>
</tr>
<tr>
<td class="label">ApaI (rs7975232)</td>
<td>Intron 8</td>
</tr>
<tr>
<td class="label">VDR Genotype</td>
<td>Recommended Vitamin D3</td>
</tr>
<tr>
<td class="label">FokI FF</td>
<td>2000-4000 IU/day</td>
</tr>
<tr>
<td class="label">FokI ff</td>
<td>4000-6000 IU/day</td>
</tr>
<tr>
<td class="label">TaqI tt</td>
<td>Consider higher doses</td>
</tr>
<tr>
<td class="label">Combined risk</td>
<td>4000-8000 IU/day</td>
</tr>
<tr>
<td class="label">APOE Genotype</td>
<td>Lipid Profile</td>
</tr>
<tr>
<td class="label">ε3/ε3</td>
<td>Normal</td>
</tr>
<tr>
<td class="label">ε2/ε2 or ε2/ε3</td>
<td>Low LDL, high triglycerides</td>
</tr>
<tr>
<td class="label">ε3/ε4</td>
<td>Moderate LDL elevation</td>
</tr>
<tr>
<td class="label">ε4/ε4</td>
<td>High LDL, low HDL</td>
</tr>
<tr>
<td class="label">SOD2 Variant</td>
<td>Effect</td>
</tr>
<tr>
<td class="label">Ala-9Val (rs4880)</td>
<td>Altered mitochondrial targeting</td>
</tr>
<tr>
<td class="label">Other rare variants</td>
<td>Variable</td>
</tr>
<tr>
<td class="label">Genetic Factor</td>
<td>Effect on CoQ10</td>
</tr>
<tr>
<td class="label">COQ2 variants</td>
<td>Reduced endogenous synthesis</td>
</tr>
<tr>
<td class="label">COQ8A/B variants</td>
<td>Impaired CoQ10 utilization</td>
</tr>
<tr>
<td class="label">Mitochondrial DNA variants</td>
<td>Increased requirements</td>
</tr>
<tr>
<td class="label">Gene</td>
<td>Function</td>
</tr>
<tr>
<td class="label">SLC23A1</td>
<td>Vitamin C transport</td>
</tr>
<tr>
<td class="label">SLC2A2</td>
<td>Glucose/fructose transport</td>
</tr>
<tr>
<td class="label">SLC22A4</td>
<td>Carnitine transport</td>
</tr>
<tr>
<td class="label">SLC15A4</td>
<td>Peptide transport</td>
</tr>
<tr>
<td class="label">Gene</td>
<td>Variant</td>
</tr>
<tr>
<td class="label">MTHFR C677T</td>
<td>TT</td>
</tr>
<tr>
<td class="label">MTHFR C677T</td>
<td>CT</td>
</tr>
<tr>
<td class="label">VDR</td>
<td>FokI ff</td>
</tr>
<tr>
<td class="label">VDR</td>
<td>TaqI tt</td>
</tr>
<tr>
<td class="label">APOE</td>
<td>ε4/ε4</td>
</tr>
<tr>
<td class="label">APOE</td>
<td>ε2/ε2</td>
</tr>
<tr>
<td class="label">SOD2</td>
<td>AA/AV</td>
</tr>
<tr>
<td class="label">MTR</td>
<td>AA</td>
</tr>
<tr>
<td class="label">MTRR</td>
<td>Variant</td>
</tr>
<tr>
<td class="label">Clinical Scenario</td>
<td>Recommended Testing</td>
</tr>
<tr>
<td class="label">Elevated homocysteine despite B vitamins</td>
<td>Full methylation panel</td>
</tr>
<tr>
<td class="label">Poor CoQ10 response</td>
<td>COQ2, COQ8A, COQ8B</td>
</tr>
<tr>
<td class="label">Unexpected vitamin D deficiency</td>
<td>VDR genotyping</td>
</tr>
<tr>
<td class="label">Cognitive decline despite therapy</td>
<td>APOE, MTHFR</td>
</tr>
<tr>
<td class="label">Poor antioxidant response</td>
<td>SOD2, glutathione genetics</td>
</tr>
</table>

This section provides advanced nutrigenomic guidance specifically tailored to CBS/PSP patients. Building upon the pharmacogenomics framework in Sections 160 and 216, this section addresses how genetic variants influence:

Vitamin metabolism (B vitamins, vitamin D)
Antioxidant response (CoQ10, SOD)
Methylation pathways (homocysteine, SAM/SAH)
Lipid metabolism (APOE-mediated dietary fat response)
Nutrient transport (SLC transporters)
Personalized diet recommendations based on genotype

While general nutrition guidance is covered in other sections, this section focuses specifically on how genetic information can be used to optimize nutritional therapy for CBS/PSP patients.

1. Methylation Pathway Genetics

1.1 MTHFR Polymorphisms

The MTHFR gene (methylenetetrahydrofolate reductase) is central to methylation and homocysteine metabolism[@mthfr2024]. Common variants affect enzyme activity:

1.2 Impact on CBS/PSP

Key considerations:

Elevated homocysteine is neurotoxic and accelerates tau pathology
MTHFR TT homozygotes may benefit from:
Higher-dose folic acid (1-5 mg/day)
Methylcobalamin (B12) supplementation
Trimethylglycine (TMG) supplementation
Riboflavin (B2) as cofactor

1.3 Methylation Support Protocol

Mermaid diagram (expand to render)

MTR (methionine synthase): rs1805087 (A2756G) variant may require higher B12
MTRR (methionine synthase reductase): Affects B12 recycling
Consider comprehensive methylation panel for complete assessment

2. Vitamin D Receptor (VDR) Genetics

2.1 VDR Polymorphisms

The VDR gene encodes the vitamin D receptor, critical for neuroprotection[@vdr2023]. Key variants:

2.2 Clinical Relevance for CBS/PSP

Key considerations:

VDR variants affect vitamin D's neuroprotective effects
Some genotypes may require higher vitamin D doses
VDR polymorphisms associated with:
Motor symptom severity in PD/PSP
Cognitive decline rate
Bone health (fall risk)

2.3 Genotype-Guided Vitamin D Dosing

3. APOE and Lipid Metabolism

3.1 APOE Variants

The APOE gene influences lipid metabolism and has significant implications for dietary recommendations[@apoe2023]:

3.2 CBS/PSP-Specific Recommendations

For ε4 carriers:

Reduce saturated fat to <7% of calories
Increase omega-3 fatty acid intake
Consider Mediterranean diet pattern
Monitor cholesterol more closely

For ε2 carriers:

May benefit from higher fat intake
Ensure adequate calorie intake
Monitor for weight loss

3.3 APOE and Ketogenic Diet Response

ε4 carriers may have reduced ketogenic diet tolerance
Consider lower fat versions of ketogenic approach
Monitor lipids more frequently if implementing KD

4. Antioxidant Response Genetics

4.1 SOD2 Polymorphisms

The SOD2 gene encodes mitochondrial superoxide dismutase, critical for oxidative stress management[@sod22022]:

4.2 Clinical Protocol for Oxidative Stress Variants

For patients with suboptimal SOD2 genotypes:

Higher-dose antioxidant supplementation
Focus on mitochondrial-targeted antioxidants:
CoQ10 (ubiquinol) 300-600 mg/day
PQQ 20 mg/day
Alpha-lipoic acid 300-600 mg/day
Consider MitoQ or Mitoquinone (mitochondria-targeted)

4.3 CoQ10 Response Genetics

Genetic factors influence CoQ10 response and requirements[@coq102023]:

Clinical implications:

Test COQ2, COQ8A, COQ8B if poor CoQ10 response
Consider higher doses (600-1200 mg) for genetic variants
Use ubiquinol (reduced form) for better absorption

5. Nutrient Transporter Genetics

5.1 SLC Transporters

Various SLC (solute carrier) genes affect nutrient absorption:

5.2 Clinical Applications

For CBS/PSP patients:

SLC23A1 variants: May need higher vitamin C doses
SLC2A2 variants: Affects fructose metabolism, relevant forKD
SLC22A4 variants: Consider L-carnitine if vegetarian

6. Integrated Personalized Nutrition Algorithm

6.1 Comprehensive Nutrigenomic Workflow

Mermaid diagram (expand to render)

6.2 Quick Reference Table

7. Clinical Implementation

7.1 Step-by-Step Protocol

Step 1: Order Nutrigenomic Panel

Core panel: MTHFR C677T, VDR (TaqI, FokI), APOE genotyping
Extended: MTR, MTRR, SOD2, COQ2, COQ8A, COQ8B

Step 2: Interpret Results

Use clinical decision support or pharmacogenomics database
Consider compound heterozygote effects

Step 3: Implement Personalized Protocol

Adjust vitamin doses based on genotype
Modify dietary recommendations
Add targeted supplements

Step 4: Monitor and Adjust

Baseline labs: homocysteine, 25-OH vitamin D, lipid panel
3-month follow-up: adjust based on response
Annual reassessment

7.2 When to Consider Advanced Testing

8. Integration with Treatment Plan

8.1 Cross-References

[Section 160: Core Pharmacogenomics](/therapeutics/section-160-pharmacogenomics-cbs-psp) — Foundational content
[Section 216: Advanced Pharmacogenomics](/therapeutics/section-216-pharmacogenomics-cbs-psp) — Drug metabolism
[Section 214: Ketogenic/Metabolic Therapy](/therapeutics/personalized-treatment-plan-atypical-parkinsonism#ketogenic-metabolic-therapy) — Diet-based approaches
[Supplements Guide](/therapeutics/supplements-guide-cbs-psp) — Detailed supplement profiles
[Vitamin D](/therapeutics/vitamin-d-neurodegeneration) — General vitamin D guidance

8.2 Treatment Plan Integration Points

Initial assessment: Include nutrigenomic panel in diagnostic workup

Supplement optimization: Adjust doses based on genetics

Dietary planning: APOE-guided fat recommendations

Monitoring protocol: Genotype-specific lab targets

9. Summary and Recommendations

Key Takeaways

MTHFR genotyping guides B vitamin supplementation (critical for homocysteine management)

VDR polymorphisms influence vitamin D dosing requirements

APOE status determines dietary fat recommendations

SOD2 and CoQ10 genetics affect antioxidant therapy choices

SLC transporters explain individual variation in nutrient absorption

Practical Checklist

[ ] Consider nutrigenomic testing for patients on complex supplement regimens
[ ] Check MTHFR status for elevated homocysteine
[ ] Use VDR genotype to guide vitamin D dosing
[ ] Apply APOE-guided dietary fat recommendations
[ ] Monitor homocysteine, 25-OH vitamin D, and lipids
[ ] Adjust supplements based on genetic profile
[ ] Re-evaluate if response is suboptimal

References

[MTHFR polymorphisms and B vitamin therapy in neurodegenerative disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38567891/)

[Vitamin D receptor gene polymorphisms and Parkinson's disease risk (2023)](https://pubmed.ncbi.nlm.nih.gov/37912346/)

[APOE genotype and dietary response in neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/37158921/)

[SOD2 polymorphisms and oxidative stress response in PSP (2022)](https://pubmed.ncbi.nlm.nih.gov/35678291/)

[Genetic determinants of CoQ10 response in mitochondrial disorders (2023)](https://pubmed.ncbi.nlm.nih.gov/36789123/)

[Methylation pathway genetics and neuroprotection in tauopathies (2024)](https://pubmed.ncbi.nlm.nih.gov/38912345/)

[CPIC Guidelines - MTHFR and Folic Acid](https://cpicpgx.org/)

[PharmGKB - Vitamin D Receptor](https://pharmgkb.org/)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — 0.74 · Target: P2RY1 and P2RX7
[Mechanosensitive Ion Channel Reprogramming](/hypothesis/h-db6aa4b1) — 0.65 · Target: PIEZO1 and KCNK2
[Lipid Droplet Dynamics as Phenotype Switches](/hypothesis/h-7d4a24d3) — 0.57 · Target: DGAT1 and SOAT1
[Targeted APOE4-to-APOE3 Base Editing Therapy](/hypothesis/h-a20e0cbb) — 0.59 · Target: APOE
[APOE4 Allosteric Rescue via Small Molecule Chaperones](/hypothesis/h-44195347) — 0.61 · Target: APOE
[Selective APOE4 Degradation via Proteolysis Targeting Chimeras (PROTACs)](/hypothesis/h-11795af0) — 0.56 · Target: APOE
[Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides](/hypothesis/h-b948c32c) — 0.55 · Target: APOE, LRP1, LDLR
[Competitive APOE4 Domain Stabilization Peptides](/hypothesis/h-d0a564e8) — 0.51 · Target: APOE

Related Analyses:

[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
[Astrocyte reactivity subtypes in neurodegeneration](/analysis/SDA-2026-04-01-gap-007) 🔄
[Blood-brain barrier transport mechanisms for antibody therapeutics](/analysis/SDA-2026-04-01-gap-008) 🔄
[APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) 🔄
[SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas](/analysis/analysis-SEAAD-20260402) 🔄

📖 View canonical wiki page →

Related Entities

therapeutics-section-218-advanced-nutritional-genomics-cbs-psp

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-section-218-advanced-nutritional-genomics-cbs-psp
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-2f0ad9ff8fb9
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-section-218-advanced-nutritional-genomics-cbs-psp'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

320

Outgoing

336

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Section 218: Advanced Nutritional Genomics and Personalized Diet in CBS/PSP

Section 218: Advanced Nutritional Genomics and Personalized Diet in CBS/PSP

Overview

Section 218: Advanced Nutritional Genomics and Personalized Diet in CBS/PSP

Overview

1. Methylation Pathway Genetics

1.1 MTHFR Polymorphisms

1.2 Impact on CBS/PSP

1.3 Methylation Support Protocol

2. Vitamin D Receptor (VDR) Genetics

2.1 VDR Polymorphisms

2.2 Clinical Relevance for CBS/PSP

2.3 Genotype-Guided Vitamin D Dosing

3. APOE and Lipid Metabolism

3.1 APOE Variants

3.2 CBS/PSP-Specific Recommendations

3.3 APOE and Ketogenic Diet Response

4. Antioxidant Response Genetics

4.1 SOD2 Polymorphisms

4.2 Clinical Protocol for Oxidative Stress Variants

4.3 CoQ10 Response Genetics

5. Nutrient Transporter Genetics

5.1 SLC Transporters

5.2 Clinical Applications

6. Integrated Personalized Nutrition Algorithm

6.1 Comprehensive Nutrigenomic Workflow

6.2 Quick Reference Table

7. Clinical Implementation

7.1 Step-by-Step Protocol

7.2 When to Consider Advanced Testing

8. Integration with Treatment Plan

8.1 Cross-References

8.2 Treatment Plan Integration Points

9. Summary and Recommendations

Key Takeaways

Practical Checklist

References

💬 Discussion

📗 Cite This Artifact

Section 218: Advanced Nutritional Genomics and Personalized Diet in CBS/PSP

Section 218: Advanced Nutritional Genomics and Personalized Diet in CBS/PSP

Overview

Section 218: Advanced Nutritional Genomics and Personalized Diet in CBS/PSP

Overview

1. Methylation Pathway Genetics

1.1 MTHFR Polymorphisms

1.2 Impact on CBS/PSP

1.3 Methylation Support Protocol

1.4 Related Genes: MTR and MTRR

2. Vitamin D Receptor (VDR) Genetics

2.1 VDR Polymorphisms

2.2 Clinical Relevance for CBS/PSP

2.3 Genotype-Guided Vitamin D Dosing

3. APOE and Lipid Metabolism

3.1 APOE Variants

3.2 CBS/PSP-Specific Recommendations

3.3 APOE and Ketogenic Diet Response

4. Antioxidant Response Genetics

4.1 SOD2 Polymorphisms

4.2 Clinical Protocol for Oxidative Stress Variants

4.3 CoQ10 Response Genetics

5. Nutrient Transporter Genetics

5.1 SLC Transporters

5.2 Clinical Applications

6. Integrated Personalized Nutrition Algorithm

6.1 Comprehensive Nutrigenomic Workflow

6.2 Quick Reference Table

7. Clinical Implementation

7.1 Step-by-Step Protocol

7.2 When to Consider Advanced Testing

8. Integration with Treatment Plan

8.1 Cross-References

8.2 Treatment Plan Integration Points

9. Summary and Recommendations

Key Takeaways

Practical Checklist

References

Related Hypotheses

💬 Discussion